DevelRx Logo

David Heal contributes to new article 'Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling'

Back to News & Events

One of our Directors, David Heal, was co-author of this new article 'Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling' which is now available online as part of a Special Issue of Neuropharmacology (National Institutes of Health Psilocybin Research Speaker Series) edited by David Heal, Jack Henningfield, Sharon Smith, Sean Belouin and Dan Xi.

You can read the paper here and find out more about the Special Issue of Neuropharmacology here

DevelRx Logo

Biocity,

Pennyfoot Street,

Nottingham,

Nottinghamshire,

NG1 1GF

inform@develrx.com

Follow us on LinkedIn

Registered in England and Wales

Company number: 12028847

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you can read our Cookie Policy for more information.